NUWE · Nuwellis, Inc.
$0.69
-0.06 (-7.37%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, including continued operating losses, negative cash flows from operations, an accumulated deficit of $325.7 million, and the need for additional capital to fund ongoing operations and growth initiatives (including the integration of Rendiatech Ltd., and Israeli company ("Rendiatech") following the Company's acquisition), raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the date these financial statements are issued. ... While management's plans, including recent financing activities, cost discipline initiatives, and contingency measures, are intended to address these conditions, such plans do not alleviate the substantial doubt.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.83M
Shares
3.65M
Volume · Oct 2
108.5K
Avg daily vol (3M)
4.34M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.69
Open$0.76
Day$0.69–0.78
52W close$0.69–146.65
Avg vol 30d3.2M
Short int38K · 1.0% float · 1.0d
Short vol35%
Last earningsAug 13, 2026
DataOct 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 6 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$9.01M
Trailing 12 months
Net income (TTM)
−$11.32M
Trailing 12 months
Revenue growth YoY
+14.1%
Year over year
Operating margin
-142.9%
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 310,579.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,981.8%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.0%
Latest settlement · 1.0 days to cover
AI Brief
Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26
TL;DR. Nuwellis (NUWE) reported Q2 2026 revenue of $2.0 million, up 14% year-over-year with U.S. revenue up 17%, while gross margin expanded to 76% from 56% and the installed base grew with 24 consoles sold in the first half versus 5 a year earlier; the company also raised approximately $12.7 million in gross proceeds, appointed a new CEO, and advanced the proposed Aquadex pediatric label expansion following an FDA pre-submission meeting.
Bullish
- + Q2 revenue grew 14% YoY to $1.97 million, with U.S. revenue up 17% and H1 revenue up 20%
- + Gross margin expanded to 76% from 56% on pricing, mix, and contract manufacturing
- + Installed base grew sharply, with 24 consoles sold in H1 versus 5 in H1 2025
- + Raised approximately $12.7 million in gross proceeds, including $6.0 million in June and ~$6.7 million post-quarter
- + Pediatric footprint expanded into two new states (Michigan and Wisconsin) plus additional South Carolina system
Bearish
- − Q2 net loss was $4.8 million, though narrower than the $12.6 million prior-year loss
- − Operating expenses rose to $4.7 million in Q2 from $3.9 million a year ago
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−98%
below
Price vs 50-day avg
−41%
below
RSI (14)
34
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−98%
trailing
YTD return
−99%
this year
Relative strength
−111%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $33 — 200d above 50d
Institutional flow
Distributing
-38% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.04% of float · ▼ -77.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
5 holders — near 3-yr low, contrarian setup
Squeeze score
30
low risk · 0–100
Fundamentals
Revenue growth
−5%
Y/Y
Gross margin
62%
contracting
EPS growth
+93%
Y/Y
Free cash flow
$-10.9M
Balance sheet
$19.2M
net cash
Quant / Vol
risk profile
Volatility
213%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
18.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−98%
Bearish
Price vs 50-day avg
−41%
Bearish
RSI (14)
34
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $33 — 200d above 50d
Institutional flow
Distributing
-38% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.04% of float · ▼ -77.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
5 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $147
vs 200-day avg -98%
vs 50-day avg -41%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| consoles sold | 24 | first half of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NUWE
this stock
Nuwellis, Inc.
|
$2.83M | — | -5.4% | — | 1.0% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.2% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
5
- % held
- 0.6%
- Net QoQ
- +12.7K sh
- Top holder
- SABBY MANAGEMENT, LLC
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NUWE | -10.6% | -5.6% | -98.4% | -3.6% | -98.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -10.4% | -5.1% | -110.5% | -4.6% | -111.7% |